John Craighead
Chief Operating Officer and Chief Financial Officer | San Francisco, California, United States
Professional Overview
John Craighead is an experienced financial and operational executive with a proven track record of driving growth and success in the biotechnology and life sciences industries. As the Chief Operating Officer and Chief Financial Officer at HALO Precision Diagnostics, he is responsible for overseeing the company's day-to-day operations, financial strategy, and corporate development initiatives.
Experience Summary
Current Role
As the Chief Operating Officer and Chief Financial Officer at HALO Precision Diagnostics, John is responsible for leading the company's overall operational and financial strategy. He oversees the execution of key business objectives, optimizes financial and resource allocation, and spearheads corporate development efforts to drive HALO's growth and innovation in the precision diagnostics space.
Career Progression
Prior to his current role, John held several senior positions in the industry, including Chief Financial Officer and Head of Corporate Development at Elpiscience Biopharmaceuticals, Vice President of Strategy, Corporate Development, and Investor Relations at GRAIL, Inc., and Vice President of Investor Relations and Corporate Communications at Atara Biotherapeutics. Throughout his career, he has demonstrated a strong ability to navigate complex financial and operational challenges, while also contributing to the strategic growth and development of the organizations he has served.
Academic Background
John holds a Bachelor of Science degree in Biochemistry from the University of California, San Diego, and a Master of Business Administration from the University of California, Los Angeles.
Areas of Expertise
- Financial management and strategic planning
- Corporate development and mergers and acquisitions
- Investor relations and stakeholder management
- Operations optimization and efficiency improvements
- Biotechnology and life sciences industry expertise
Professional Impact
During his tenure at GRAIL, John played a pivotal role in the company's successful initial public offering and subsequent corporate development initiatives. At Atara Biotherapeutics, he led the company's investor relations and corporate communications efforts, effectively communicating the organization's strategic vision and product pipeline to the investment community.
Conclusion
With his extensive industry experience, strong financial acumen, and proven track record of driving operational excellence, John Craighead is well-positioned to lead HALO Precision Diagnostics through its next phase of growth and innovation. His versatile skill set and strategic mindset make him a valuable asset to the organization as it continues to push the boundaries of precision diagnostics.
